Case study: Identifying allosteric modulators for GPCRs

Posted: 25 January 2021 | | 1 comment

Identifying allosteric modulators and biased agonists for clinically relevant GPCRs. Case Studies using Eurofins Discovery’s GPCR product solutions.

The sheer number of understudied and orphan receptors in the GPCR family have made them an attractive target for many drug discovery programs. These targeted clinical candidates have the potential to minimize side-effects associated with unbiased orthosteric GPCR activation. Developing methods to measure signaling bias has proven to be a major barrier in the development of new GPCR therapies – a barrier that Eurofins Discovery has actively worked to deconstruct.


One response to “Case study: Identifying allosteric modulators for GPCRs”

  1. Isatou Sarr says:

    GPCRs have been highly understudied in the context of COVID-19 and given that they are cell surface receptors and the COVID-19 S (spike) protein has been implicated in invasion/pathogenesis and therapeutic poor response, it will be interesting to understnad the interaction between GPCRs and COVID-19 as well as in relation to other pathogens that may be drivers of infection in COVID cases such as other coronaviruses/respiratory and non respiratory pathogens.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.